M. Foxton

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Matthew R Foxton, M R Foxton, Matthew Foxton, Matthew R. Foxton, M Foxton, M. Foxton
Publication record
46 papers · 1,241 citations · H-index 14

PAPERS

The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer: The Royal Marsden Hospital Experience
20230 citationsauthor #9
Regional variation in characteristics of patients with decompensated cirrhosis admitted to hospitals in the UK.
20237 citationsauthor #84
P32 Cascade of care for chronic hcv infection in a large homeless metropolitan population
20230 citationsauthor #16
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]
20211 citationsauthor #300
X chromosome contribution to the genetic architecture of primary biliary cholangitis.
202142 citationsauthor #139
P381 Defining HCV cirrhosis by Fibroscan score has a significant impact on HCC surveillance burden
20210 citationsauthor #8
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
2021132 citationsauthor #312
Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature
202020 citationsauthor #2
PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity.
20197 citationsauthor #3
Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis.
2019142 citationsauthor #9
Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience.
20195 citationsauthor #7
HIV/HCV/HBV testing in the emergency department: a feasibility and seroprevalence study
201827 citationsauthor #9
Real world experience of direct acting antiviral agents in hepatitis C virus genotype 4: encouraging outcomes from a UK-based cohort
20170 citationsauthor #4
Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation
201710 citationsauthor #3
Improving the Diagnostic Criteria for Primary Liver Graft Nonfunction in Adults Utilizing Standard and Transportable Laboratory Parameters: An Outcome‐Based Analysis
201731 citationsauthor #4
Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase
201657 citationsauthor #14
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways
2015295 citationsauthor #129
A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma
201525 citationsauthor #8
OC-021 Monocyte oxidative burst defect is associated with susceptibility to infection in severe alcoholic hepatitis
20151 citationsauthor #10
P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS
20140 citationsauthor #16
CXCL10 levels identify individuals with rapid fibrosis at 12 months post‐transplant for hepatitis C virus and predict treatment response
20148 citationsauthor #3
An identification and brief advice programme for low-risk alcohol consumption in an acute medical setting: an implementation study
20133 citationsauthor #8
565 INTERFERON GAMMA INDUCIBLE PROTEIN (IP)-10 LEVELS IDENTIFY INDIVIDUALS WITH RAPID FIBROSIS AT 12 MONTHS POST-TRANSPLANT FOR HCV
20130 citationsauthor #3
Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy
201340 citationsauthor #2
The association of pretransplant ferritin level with waiting list and post‐transplant survival. Does ferritin actually predict outcome?
201313 citationsauthor #3
PTU-020 Rifaxamin is a highly efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy (HE)
20120 citationsauthor #3
P71 A model to improve performance of current category 9 UK listing criteria: early liver graft dysfunction. A single centre cohort
20110 citationsauthor #4
Gallstones: An Undescribed Cause of Severe Hepatitis
20110 citationsauthor #4
Serum Ferritin Concentration May Predict Waiting List Mortality: Evaluation of a Cohort of 1776 Patients
20110 citationsauthor #3
OP05 The impact of comorbidities on outcome of patients assessed for liver transplantation, waiting list mortality and post liver transplantation survival using the Charlson comorbidity index
20110 citationsauthor #6
PWE-028 Thiopurine-induced neutropaenia in IBD patients with normal TPMT levels: a warning for gastroenterologists
20100 citationsauthor #3
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation
201028 citationsauthor #3
Increased model for end‐stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs
201095 citationsauthor #1
Surprise finding at endoscopic retrograde cholangiopancreatography.
20101 citationsauthor #2
S1269 Screening, Referral Practice and Management of Hepatitis B and C in Primary Care: A Survey of General Practitioners
20100 citationsauthor #4
PTU-072 Screening, referral practice and management of hepatitis B and C in primary care: a survey of general practitioners
20100 citationsauthor #4
W1031 Follow-up of Patients With Iron Deficiency Anemia Subsequent to Negative Upper and Lower Gastrointestinal Investigations
20101 citationsauthor #3
A MODEL TO PREDICT RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
20100 citationsauthor #1
P104 Serum ferritin concentration may predict waiting list mortality but not independent of model for end-stage liver disease score: evaluation of a cohort of 422 patients
20100 citationsauthor #2
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease
200695 citationsauthor #8
The Impact of Diabetes Mellitus on Fibrosis Progression in Patients Transplanted for Hepatitis C
2006125 citationsauthor #1
136 Artificial neural network is superior to meld in predicting mortality of patients with end-stage liver disease
20061 citationsauthor #9
Change in model for end‐stage liver disease score on the transplant waiting list predicts survival in patients undergoing liver transplantation
200612 citationsauthor #1
Liver transplantation for HCV‐related cirrhosis in a patient with gastric mucosa‐associated lymphoma (MALToma) pretreated with rituximab
200511 citationsauthor #1
Haemophagocytic lymphohistiocytosis post liver transplantation
20040 citationsauthor #3
Management of cirrhosis and ascites.
20044 citationsauthor #2

TIMELINE

2004 4 citations

2005 11 citations

2006 233 citations

2010 125 citations

2011 0 citations

2012 0 citations

2013 56 citations

2014 8 citations

2015 321 citations

2016 57 citations

2017 41 citations

2018 27 citations

2019 154 citations

2020 20 citations

2021 175 citations

2023 7 citations

M. Foxton

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT